Copy-number variations in hepatoblastoma associate with unique clinical features

Area of Science:

• Pediatric Oncology
• Cancer Genomics
• Molecular Biology

Background:

• Hepatoblastoma is a rare childhood liver cancer.
• Limited cytogenetic data exists for hepatoblastoma.
• Understanding genomic alterations is crucial for prognosis.

Purpose of the Study:

• Identify common genomic copy-number variations (CNVs) in hepatoblastoma.
• Determine the clinical relevance of these CNVs.
• Explore potential biomarkers for patient outcomes.

Main Methods:

• Comparative genomic hybridization (CGH) DNA oligonucleotide microarray used for gene copy-number assessment.
• Study included 12 hepatoblastoma patients and 20 healthy controls.
• Analysis of recurrent CNVs and their association with clinical outcomes.

Main Results:

• Four recurrent CNVs identified: gain at 1p13.3 and losses at 5p15.33, 16q12.2, and 19q13.42.
• Losses at 5p15.33 and 16q12.2 were most prevalent (33.3% each).
• 5p15.33 deletions (containing ZDHHC11/ZDHHC11B) correlated with lower survival with native liver (p=0.03).
• 16q12.2 deletions (containing CES4) associated with smaller tumor size.

Conclusions:

• Frequent CNVs in hepatoblastoma include deletions at 5p15.33 and 16q12.2.
• Microdeletion at 5p15.33 is a potential biomarker for survival with native liver.
• Genomic alterations provide insights into hepatoblastoma pathogenesis and prognosis.